Welcome to our 2023 Q2 newsletter! We hope this finds you well and that you're excited to dive into the latest updates from Vita Group. In this edition, we have some exciting announcements to share with you, including news on Brekka and StingRay, project updates, and an important new hire to the company.
As always, we thank you for your continued support and we hope you enjoy this latest edition.
Brekka & StingRay Implant Delivery Medical Device Updates
After 3 years of dedicated g research, development, and collaboration with top medical professionals, we are proud to bring these innovative solutions to the market.
First Cases Completed
In our pursuit of advancing implant delivery procedures, we drew inspiration from the challenges faced by surgeons. Our unwavering focus led us to develop devices that address these challenges head-on, simplifying the process, enhancing precision, and ultimately improving patient outcomes.
Collaborating closely with esteemed Key Opinion Leaders (KOLs), Dr. Chopra and Dr. Joe Gryskiewicz, we are proud to share that multiple cases utilizing Brekka and StingRay have yielded fantastic results. Their expertise and invaluable insights have further validated the effectiveness and transformative potential of these innovative devices.
Since we already have high demand from surgeons eager to incorporate these devices into their practices, we released the entire inventory of 1,000 Brekka and 1,000 StingRay units to our dedicated team of 38 sales individuals. The response has been overwhelming, with an average of 30 to 40 orders pouring in daily.
In line with our commitment to meeting the growing demand, we plan to produce 2,000 units of StingRay and Brekka in July and another 5,000 units in August to ensure an ample supply to meet the rising demand.
StingRay and Brekka are listed at $200 per unit. New practices are advised to reach out through the associated website's forms to request a trial. We understand the importance of accessibility and affordability in the medical device market, and our pricing strategy reflects our commitment to ensuring these innovative solutions are within reach for healthcare professionals worldwide.
Brekka Medical Device Meets Mayo Clinic
To add to the excitement, we are delighted to share that the Brekka device has been approved for a significant milestone. Starting in Q3 of this year, Brekka will undergo a three-week trial at the renowned Mayo Clinic in Rochester, MN. This collaboration with such a prestigious institution highlights the confidence and recognition our device has garnered in the medical community.
Follow us to stay up to date on the latest developments, success stories, and upcoming events related to StingRay and Brekka.
Brekka Ordering: www.brekkamedical.org
Brekka Request Trial Information: www.brekkamedical.org/pages/contact
Brekka LinkedIn: brekkamedical
Brekka Instagram: brekkamedical
StingRay Ordering: www.stingraymedical.org
StingRay Request Trial Information: www.stingraymedical.org/pages/contact
StingRay LinkedIn: stingraymedical
StingRay Instagram: stingraymedical
The Only Vertically Integrated Medical Device Incubator
Vita Group is on its way to revolutionizing the medical device incubator industry through vertical integration. We will be the only medical device company in the U.S. to offer research and development, regulatory expertise, manufacturing capabilities, sterilization services, distribution channels, and sales operations all under one roof.
This distinctive model offers numerous advantages to our partners and investors. Firstly, by consolidating all essential processes, Vita Group (Soon to be VitaTek) eliminates the need for multiple third-party vendors and streamlines operations. This translates to reduced costs, improved timelines, and enhanced quality control.
Furthermore, our vertically integrated structure fosters collaboration and knowledge-sharing across departments. Our talented team of engineers, scientists, regulatory specialists, and sales professionals work hand in hand to ensure seamless transitions throughout the development process. This synergy enables us to respond rapidly to market needs, make informed decisions, and deliver exceptional products that meet the highest industry standards.
At VitaTek, we understand the critical importance of speed to market. Our integrated approach expedites the product development journey, allowing us to bring innovative medical devices to patients swiftly and efficiently. By eliminating the need for intermediaries, we eliminate delays, enhance communication, and maintain a sharp focus on meeting project milestones.
Streamlining EO Sterilization
We are thrilled to announce the imminent installation of EO (Ethylene Oxide) Sterilization units this quarter. This strategic investment in EO sterilization technology marks a significant milestone for VitaTek as we further expand our capabilities toward vertical integration.
While traditional sterilization processes can take half of a year to complete, our streamlined approach ensures that devices are swiftly processed and ready for market sooner. By integrating the EO sterilization process within our facility, we eliminate the need for outsourcing, minimizing wait times and reducing overall project timelines.
VitaTek offers an Accelerator Option that completes protocol, validation, and engineering runs in 4 weeks! We hold weekly meetings to review progress until the project is completed to provide important communication and ensure project meets the Accelerator Timeline.
The Largest Private Medical Device Manufacturer In MN
As the largest private medical device manufacturer in the state, we are dedicated to optimizing our operations and creating a unified presence that maximizes efficiency and fosters collaboration. Currently, VitaTek boasts four strategically located facilities throughout Minnesota, each serving a specific purpose within our vertically integrated model. With over 150,000 square feet of manufacturing space combined, we have built a robust infrastructure to support our growing portfolio of innovative medical devices.
We are delighted to share that our new location at 390 Commerce Drive is making significant progress through the State Approval process. Furthermore, we anticipate City approval for our new location to be completed within two weeks. With this timeline in mind, Vita Group plans to initiate the transition to the VitaTek location in Q3. This strategic move will enable us to bring together our resources under one roof, fostering collaboration, streamlining communication, and enhancing operational efficiency.
Over the past few months, we have been signing on projects at an accelerated pace, signing on seven new projects with a diverse range of specialties and applications. This expansion allows us to broaden our scope and tackle a wider array of devices, catering to various medical fields, from general surgery to innovative at-home solutions.
Moreover, our success goes beyond project signings. We currently have five projects in acceleration, where we are leveraging our expertise and resources to expedite their development. These projects, which show immense promise, are progressing at an accelerated pace, thanks to our dedicated team of engineers, designers, and regulatory experts.
In addition to our accelerated projects, we have an impressive lineup of 28 projects in incubation. Our collaborative and vertically-integrated approach allows us the ability to push the boundaries of what is possible in the medical device industry. Each project presents a unique opportunity to collaborate with passionate inventors and physicians who are dedicated to improving patient care.
Meet Our New President of Sales, Matt Newman
We are delighted to announce the addition of Matt Newman as our newest owner, partner, and President of Sales. Matt brings a wealth of experience in the medical device sales industry and is poised to make a significant impact on our organization.
With an extensive background in medical device sales, Matt possesses a deep understanding of the market dynamics and the intricate nuances that drive success in this industry. His proven track record of building strong client relationships and driving business growth aligns perfectly with VitaTek's vision and goals.
Matt will play a pivotal role in expanding our sales footprint, fostering strategic collaborations, and driving customer acquisition efforts. His insights and expertise will help us further strengthen our market position and solidify our reputation as a trusted and preferred provider of cutting-edge medical devices.
We warmly welcome Matt to the team and are excited about the value and contributions he will bring to our organization.
Thank you for reading this edition of Q2 2023 Newsletter. We hope you enjoyed the updates, and you can expect our Q3 2023 Newsletter at the end of September. To learn more, visit us at www.vitagroup.io. If you have questions about the medical incubation process and want to learn more, book a time to meet with our CEO Jason Scherer.